[Skip to Navigation]
July 1974

Hypothalamic Releasing Factors and Parkinson Disease

Author Affiliations

Bethesda, Md; Chapel Hill, NC
From the Neurology Unit, National Institute of Mental Health, Bethesda, Md (Drs. Chase and Woods), and the departments of psychiatry (Dr. Lipton) and neurology (Dr. Morris), University of North Carolina School of Medicine, Chapel Hill.

Arch Neurol. 1974;31(1):55-56. doi:10.1001/archneur.1974.00490370081013

Therapeutic trials of intravenously infused thyrotrophin-releasing hormone or melanocyte-stimulating hormone releaseinhibiting factor were conducted in patients with idiopathic parkinsonism. Thyrotrophin-releasing hormone had no consistent effect on extrapyramidal function in five otherwise untreated patients, nor did it significantly modify the response to levodopa in six other individuals. Melanocyte-stimulating hormone release-inhibiting factor exerted a mild amelioratory effect in three of six untreated patients, while in five levodopatreated individuals antiparkinsonian efficacy was potentiated in two and dyskinesias increased in three. In neither group, however, did these effects attain statistical significance.

Add or change institution